SMAD2 and SMAD3 are the main downstream effectors of TGF-β, and despite their 84% protein sequence homology and similar activation patterns, there is growing evidence that SMAD2 and SMAD3 play different and opposing functions including cell invasion, tumour growth, and metastasis [183,184,185]. This evidence concerns the gene SMAD3 and neoplasm.